Disclaimer

The system provides an estimate of in vivo efficacy of commonly used antiretroviral drug combinations based on user-defined information of HIV genotype (mandatory) and additional patient information (recommended). The engine is not intended as a replacement for standard of care but can be used by HIV specialists as an additional treatment decision support tool. Although analysis of a large data set of medical records has shown a good performance of the system, there is no warranty that its use will improve patient health. HIV care must rely on a solid knowledge of the complex host-virus interaction and proper consideration of patient status and commitment.

Regimens notes

The EuResist engine is based on statistical learning and thus cannot predict the activity of drug regimens not yet included in a suitable amount in the training dataset. At the moment, Enfuvirtide, Raltegravir and Maraviroc are not considered. If you intend to use one or more of these drugs, you may want to restrict the output to 2-drug regimens only. Likewise, you can easily select or unselect whole drug classes to build your preferred regimen.

The current version of the engine computes the activity of the drug combinations listed in the table below. Please note that some regimens are now uncommon in high-income countries but may be an option in low/middle-income countries.

Drug combination Notes
2 NRTIs + 1 NNRTI
2 NRTIs + 1 PI
2 NRTIs + 1 NNRTI + 1 PI
1 NRTI + 1 NNRTI + 1 PI
1 NNRTI + 1 PI Two-drug regimen intended to be completed with another drug not considered by the system such as enfuvirtide, raltegravir, maraviroc
1 NRTI + 1 PI Two-drug regimen intended to be completed with another drug not considered by the system such as enfuvirtide, raltegravir, maraviroc
1 NRTI + 1 NNRTI Two-drug regimen intended to be completed with another drug not considered by the system such as enfuvirtide, raltegravir, maraviroc
AZT + 3TC + ABC

Trizivir allowed as the only NRTI-only regimen for special patients
AZT + 3TC + ABC + 1 NNRTI Trizivir plus 1 NNRTI
AZT + 3TC + ABC + 1 PI Trizivi plus 1 PI

Additional notes

  • NRTI combos considered include: AZT/3TC, TDF/3TC, ABC/3TC, AZT/TDF, DDI/3TC, D4T/3TC, AZT/DDI.
  • PIs are all considered with boosting ritonavir with the only possible exception of Atazanavir.
  • The following drugs are not considered any more due to their infrequent use worldwide: Delavirdine, Zalcitabine, Nelfinavir.